ADMP Stock Falls 50%: FDA Rejects Opioid Overdose Treatment Zimhi
ADMP is one of the biggest losers in the health sector on Monday after Adamis Pharmaceuticals Corp (NASDAQ:ADMP) said that the US Food and Drug Administration did not approve its opioid overdose treatment, Zimhi. Major ... [Read]
Adamis Pharmaceuticals’ Shares Hits New Highs After Allergic-Reaction Treatment Drug Gains FDA Approval
Investors in Adamis Pharmaceuticals Corp. (NASDAQ:$ADMP) were probably celebrating yesterday as the company’s shares flew through the roof by a whopping 53%, hitting a one-year high. The rise was largely due to Adamis’ announcement that ... [Read]